IOCAB 2025 Conference

The 1st International Online Conference by *Antibodies*. Therapeutic Antibodies: New Trends in Discovery, Developability and Characterization

13–14 October 2025 | Online

Chaired by Prof. Dr. Arne Skerra

antibodies MDPI

THE ART OF IMMUNE SUPRESSION: AN ANTIBODY PERSPECTIVE

R.Prem Sai, R.Harsha Vardhan, D.Yaswanth
B.Pharm 4th year, Narayana Pharmacy College, Nellore, Andhra Pradesh, India

INTRODUCTION & AIM

The immune system is essential for defending the body against infections and maintaining internal balance. However, in conditions like organ transplant rejection and autoimmune diseases such as Neuromyelitis Optica Spectrum Disorder (NMOSD), immune responses can become harmful. NMOSD, This disorder, comprising six syndromes, is intricately linked to aquaporin-4 immunoglobulin G antibodies (AQP4-IgG), necessitating serologic testing for accurate evaluations.Chronic immunosuppressive therapy can be accomplished with azathioprine or rituximab as first-line agents to treat NMOSD This course will delve into the diverse clinical manifestations To manage such immune-mediated damage, therapeutic antibodies have emerged as targeted tools that suppress pathological immune activity while preserving overall immunity. AIM: This poster explores the evolving role of antibody-based immune suppression in both autoimmunity and transplant medicine. It highlights key mechanisms including B-cell depletion, cytokine inhibition, and complement blockade. Clinical examples such as rituximab, satralizumab, and eculizumab in NMOSD, and agents like basiliximab in transplant cases, illustrate how these therapies reduce disease activity and prevent tissue rejection. The aim is to underscore the precision, safety, and therapeutic value of antibody-mediated immune modulation

METHOD

This study involved a comprehensive review of current literature and clinical data focusing on antibody-mediated immune suppression. Relevant scientific articles, clinical trial reports, and treatment guidelines were sourced from databases including PubMed, Google Scholar, and ClinicalTrials.gov using keywords such as immune suppression, therapeutic antibodies, Neuromyelitis Optica Spectrum Disorder (NMOSD), AQP4-IgG, and organ transplant rejection. Selected studies emphasized therapeutic antibodies that modulate immune responses through mechanisms like B-cell depletion, cytokine inhibition, and complement blockade. Antibody therapies reviewed included rituximab, eculizumab, satralizumab, and basiliximab, among others. Comparative analysis of these therapies considered clinical efficacy, safety profiles, and impact on immune regulation. The aim was to identify how these biologics refine immune suppression, particularly in autoimmune diseases such as NMOSD and in preventing transplant rejection, while minimizing systemic immune compromise.



RESULTS & DISCUSSION

ASPECT	NMOSD (Neuromyelitis Optica Spectrum Disorder)	Organ Transplantation
Primary Goal	Suppress autoimmune attack on CNS	Prevent rejection of transplanted organ
Immune Target	B cells (antibody-producing)	T cells (cell-mediated rejection)
Mechanism of Damage	Autoantibodies (e.g., anti-AQP4) attack optic nerves and spinal cord	Host T cells attack the foreign graft
Key Monoclonal Antibodies	- Rituximab- Inebilizumab- Eculizumab	- Basiliximab- Alemtuzumab
Mode of Action	- B cell depletion (CD20+, CD19+ cells)- Complement inhibition	- T cell suppression (IL-2 receptor blockade, lymphocyte depletion)
Clinical Benefits	- Reduced relapse rates- Slower disease progression- Better visual and motor outcomes	- Reduced acute rejection- Longer graft survival- Less need for toxic conventional drugs
Monitoring Needs	Regular monitoring of B cell counts, antibody titers, relapse signs	Monitoring of graft function, T cell activity, signs of rejection
Challenges	- Risk of infections- Limited long-term data for newer agents	- Risk of over-immunosuppression- Infection and malignancy risk
Treatment Personalization	Based on AQP4-antibody status and relapse severity	Based on organ type, donor match, and rejection risk
Outcome Focus	Preserve CNS function and quality of life	Prolong organ function and patient survival



CONCLUSION

Antibody-based therapies offer targeted immune suppression with fewer side effects. In NMOSD, they help prevent relapses by controlling harmful immune activity. For transplant patients, they reduce graft rejection by modulating the immune response. These advances bring safer, more effective treatment options for immune-related conditions.

FUTURE WORK / REFERENCES

Neuromyelitis Optica Spectrum Disorder (NMOSD)
Authors: Caleb L. Shumway; Bhupendra C. Patel; Koushik Tripathy; Orlando De Jesus.